

# Melissa K Hallow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6298469/publications.pdf>

Version: 2024-02-01

24  
papers

821  
citations

758635

12  
h-index

642321

23  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1226  
citing authors

#	ARTICLE	IF	CITATIONS
1	Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 479-487.	2.2	336
2	Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F819-F835.	1.3	74
3	A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2014, 306, R647-R662.	0.9	60
4	A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in R. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 3-10.	1.3	60
5	Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1295-F1306.	1.3	46
6	A Quantitative Systems Physiology Model of Renal Function and Blood Pressure Regulation: Model Description. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 383-392.	1.3	36
7	Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 380-395.	1.3	33
8	Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S39-S46.	1.9	25
9	A Quantitative Systems Physiology Model of Renal Function and Blood Pressure Regulation: Application in Salt-Sensitive Hypertension. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 393-400.	1.3	20
10	Multiscale Mathematical Model of Drug-Induced Proximal Tubule Injury: Linking Urinary Biomarkers to Epithelial Cell Injury and Renal Dysfunction. <i>Toxicological Sciences</i> , 2018, 162, 200-211.	1.4	20
11	Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 377-385.	1.0	20
12	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 720-725.	2.2	15
13	The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet. <i>Kidney International Reports</i> , 2022, 7, 1084-1092.	0.4	12
14	Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice. <i>Npj Systems Biology and Applications</i> , 2018, 4, 2.	1.4	11
15	Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis. <i>PLoS Computational Biology</i> , 2020, 16, e1008074.	1.5	11
16	Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-CHF Study Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 636-648.	1.0	9
17	Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 76-91.	1.3	8
18	Cardiorenal Systems Modeling: Left Ventricular Hypertrophy and Differential Effects of Antihypertensive Therapies on Hypertrophy Regression. <i>Frontiers in Physiology</i> , 2021, 12, 679930.	1.3	6

#	ARTICLE	IF	CITATIONS
19	A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2022, 49, 471-486.	0.8	6
20	Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 15-25.	0.8	5
21	Exposure-response modeling of flow-mediated dilation provides an unbiased and informative measure of endothelial function. <i>Journal of Applied Physiology</i> , 2017, 122, 1292-1303.	1.2	4
22	Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 541-554.	1.0	2
23	Mathematical modeling of left ventricle hypertrophy and dilatation in response to volume overload in heart failure: a coupled renal-cardiac model. <i>FASEB Journal</i> , 2018, 32, 903.22.	0.2	0
24	Effect of URAT1 inhibition with verinurad on proximal tubule intracellular lactate: A mathematical modeling analysis and hypothesis for antiproteinuric effect. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0